Oral News and Research

RSS

Soligenix receives FDA Fast Track designation for SGX203 to treat pediatric Crohn's disease

Soligenix, Inc., a development stage biopharmaceutical company, announced today that its program for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of mild-to-moderate pediatric Crohn's disease has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA).

8 Nov 2012

Diabetic foot complication risk highlighted in men

Men should be considered for aggressive treatment for foot complications associated with diabetes, such as ulceration and amputation, say researchers.

8 Nov 2012

Oral verrucous lesions need special diagnostic attention

Care should be taken to diagnose oral verrucous lesions accurately according to their nature, behavior, and malignant potential, and should be differentiated from grade I squamous cell carcinoma, suggest Indian researchers.

8 Nov 2012

Canine lymphoma treatment adds up to cystitis

High cumulative doses of the alkylator cyclophosphamide could be to blame for the development of sterile hemorrhagic cystitis in dogs being treated for lymphoma, indicate the results of a US study.

8 Nov 2012

Synthetic cannabinoid could treat pain in diabetes patients

Oral synthetic cannabinoid nabilone may be effective for treating diabetic peripheral neuropathic pain, a study shows.

8 Nov 2012

Atherotech VAP Lipid Panel demonstrates accuracy in personalized heart disease risk assessment

Researchers using the Atherotech VAP Lipid Panel demonstrated the comprehensive lipid profile's accuracy in risk stratification through subclass measurement in two abstracts presented today at the American Heart Association (AHA) Scientific Sessions 2012.

8 Nov 2012

Metformin more effective than sulfonylurea in controlling type 2 diabetes

A Vanderbilt study examining the impact of the two most commonly prescribed oral diabetes medications on the risk for heart attack, stroke and death has found the drug metformin has benefits over sulfonylurea drugs.

8 Nov 2012

Arisaph’s ARI-3037MO well tolerated in healthy male and female volunteers

Arisaph Pharmaceuticals, Inc. announced today during an oral presentation at the American Heart Association (AHA) meeting in Los Angeles, CA that its niacin analog, ARI-3037MO, was extremely well tolerated in a single-ascending dose (SAD) and a multiple-ascending dose (MAD) trial in healthy male and female volunteers.

7 Nov 2012

Elafin protein protects against inflammatory diseases

This protection is provided by a human protein, Elafin, which is artificially introduced into dairy produce bacteria (Lactococcus lactis and Lactobacillus casei). In time, this discovery could be useful for individuals suffering from chronic inflammatory diseases such as Crohn's disease or ulcerative colitis.

7 Nov 2012

Characteristics of both patient and surgeon can affect dental implants’ success

Characteristics of both patient and surgeon can affect the success of dental implants. A 10-year study finds that patient risk factors such as grinding teeth or diabetes increase the odds of implant failure. It also associates higher implant failure rates with surgeons who have less than 5 years of experience.

7 Nov 2012

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts.

7 Nov 2012

Turning off GSK-3α protein activity can prevent heart remodeling

When a person has a heart attack, portions of the heart muscle die in the next several days or even weeks if deprived of oxygen for long enough. The recovering heart slowly remodels itself, even fostering the growth of new blood vessels, in an attempt to regain some of its former function. But all too often, the remodeling is actually harmful, and the damaged heart is on an inevitable downward slide to heart failure.

6 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

Phantom caries revealed?

Microcomputed tomography of teeth can detect demarcated radiolucencies below the enamel–dentin junction that are of noncarious origin, and can therefore be classified as possible developmental irregularities, show study results.

6 Nov 2012

State roundup: Examining health issues on state ballots

Sprinkled throughout ballots across the country are state initiatives that run the gamut from education to animal rights to marriage. And health care is well-represented, too. The National Conference of State Legislatures labels health a "key issue" in this cycle's roundup of state ballot questions.

6 Nov 2012

Midwest symposium to discuss new concepts for tissue-specific regenerative medicine

Hoxworth Blood Center, the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center will host the Midwest Symposium on New Concepts For Tissue-Specific Regenerative Medicine, Nov 17-18, 2012, in Rieveschl Auditorium of the Vontz Center for Molecular Studies.

6 Nov 2012

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).

3 Nov 2012

FDA expands Janssen’s Xarelto use to reduce risk of DVT and PE

The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.

3 Nov 2012

Genkyotex announces positive results from GKT137831 Phase I studies on healthy subjects

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.

3 Nov 2012